BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 27235861)

  • 1. Vascular disrupting activity of combretastatin analogues.
    Porcù E; Salvador A; Primac I; Mitola S; Ronca R; Ravelli C; Bortolozzi R; Vedaldi D; Romagnoli R; Basso G; Viola G
    Vascul Pharmacol; 2016 Aug; 83():78-89. PubMed ID: 27235861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis.
    Porcù E; Viola G; Bortolozzi R; Persano L; Mitola S; Ronca R; Presta M; Romagnoli R; Baraldi PG; Basso G
    Angiogenesis; 2013 Jul; 16(3):647-62. PubMed ID: 23456551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Novel Antitubulin Agent TR-764 Strongly Reduces Tumor Vasculature and Inhibits HIF-1α Activation.
    Porcù E; Persano L; Ronca R; Mitola S; Bortolozzi R; Romagnoli R; Oliva P; Basso G; Viola G
    Sci Rep; 2016 Jun; 6():27886. PubMed ID: 27292568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent.
    Ren X; Dai M; Lin LP; Li PK; Ding J
    Br J Pharmacol; 2009 Apr; 156(8):1228-38. PubMed ID: 19302593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cryptotanshinone inhibits VEGF-induced angiogenesis by targeting the VEGFR2 signaling pathway.
    Xu X; Wu L; Zhou X; Zhou N; Zhuang Q; Yang J; Dai J; Wang H; Chen S; Mao W
    Microvasc Res; 2017 May; 111():25-31. PubMed ID: 28040437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.
    Chen H; Cong Q; Du Z; Liao W; Zhang L; Yao Y; Ding K
    Cancer Lett; 2016 Nov; 382(1):44-52. PubMed ID: 27569654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.
    Zhang JT; Fan YZ; Chen CQ; Zhao ZM; Sun W
    Int J Oncol; 2012 May; 40(5):1501-14. PubMed ID: 22200632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel tubulin antagonist pretubulysin displays antivascular properties in vitro and in vivo.
    Kretzschmann VK; Gellrich D; Ullrich A; Zahler S; Vollmar AM; Kazmaier U; Fürst R
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):294-303. PubMed ID: 24285578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological and anti-vascular activity evaluation of ethoxy-erianin phosphate as a vascular disrupting agent.
    Yuan W; Su C; Yang X; Li Y; Cao Y; Liang X; Liu J
    J Cell Biochem; 2019 Oct; 120(10):16978-16989. PubMed ID: 31111562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis inhibition by the maleimide-based small molecule GNX-686.
    Nowak-Sliwinska P; Storto M; Cataudella T; Ballini JP; Gatz R; Giorgio M; van den Bergh H; Plyte S; Wagnières G
    Microvasc Res; 2012 Mar; 83(2):105-10. PubMed ID: 22056402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF.
    Hosseini H; Rajabibazl M; Ebrahimizadeh W; Dehbidi GR
    Microvasc Res; 2015 Jan; 97():13-8. PubMed ID: 25250517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects.
    Jiang Z; Wu M; Miao J; Duan H; Zhang S; Chen M; Sun L; Wang Y; Zhang X; Zhu X; Zhang L
    Int J Biochem Cell Biol; 2013 Aug; 45(8):1710-9. PubMed ID: 23702033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis.
    Xiao L; Yang S; Hao J; Yuan X; Luo W; Jiang L; Hu Y; Fu Z; Zhang Y; Zou C
    Cancer Lett; 2015 Apr; 359(1):148-54. PubMed ID: 25597785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nelumbo nucifera Gaertn leaves extract inhibits the angiogenesis and metastasis of breast cancer cells by downregulation connective tissue growth factor (CTGF) mediated PI3K/AKT/ERK signaling.
    Chang CH; Ou TT; Yang MY; Huang CC; Wang CJ
    J Ethnopharmacol; 2016 Jul; 188():111-22. PubMed ID: 27178635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-angiogenic effect of adiponectin in human primary microvascular and macrovascular endothelial cells.
    Palanisamy K; Nareshkumar RN; Sivagurunathan S; Raman R; Sulochana KN; Chidambaram S
    Microvasc Res; 2019 Mar; 122():136-145. PubMed ID: 30144414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SKLB-M8 induces apoptosis through the AKT/mTOR signaling pathway in melanoma models and inhibits angiogenesis with decrease of ERK1/2 phosphorylation.
    Wang J; Yang Z; Wen J; Ma F; Wang F; Yu K; Tang M; Wu W; Dong Y; Cheng X; Nie C; Chen L
    J Pharmacol Sci; 2014; 126(3):198-207. PubMed ID: 25341684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
    Gao W; Jin K; Lan H; Han N; Cao F; Teng L
    Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of alpha-tocopherol ether-linked acetic acid in VEGF-induced angiogenesis and the possible mechanisms in human umbilical vein endothelial cells.
    Chuang CH; Liu CH; Lu TJ; Hu ML
    Toxicol Appl Pharmacol; 2014 Dec; 281(3):310-6. PubMed ID: 25447407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-angiogenic effect of furanodiene on HUVECs in vitro and on zebrafish in vivo.
    Zhong ZF; Hoi PM; Wu GS; Xu ZT; Tan W; Chen XP; Cui L; Wu T; Wang YT
    J Ethnopharmacol; 2012 Jun; 141(2):721-7. PubMed ID: 21911050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Danshensu has anti-tumor activity in B16F10 melanoma by inhibiting angiogenesis and tumor cell invasion.
    Zhang LJ; Chen L; Lu Y; Wu JM; Xu B; Sun ZG; Zheng SZ; Wang AY
    Eur J Pharmacol; 2010 Sep; 643(2-3):195-201. PubMed ID: 20621088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.